Harrow, Inc. Long-Term Debt, Maturity, Year Two
Harrow, Inc. (HROW) had Long-Term Debt, Maturity, Year Two of $0 as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-08-10
- 2026-06-30: Long-Term Debt, Maturity, Year Two $0.00.
- 2025-09-30: Long-Term Debt, Maturity, Year Two $21.56M.
- 2025-06-30: Long-Term Debt, Maturity, Year Two $45.03M.
- 2025-03-31: Long-Term Debt, Maturity, Year Two $45.03M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 |
| 2025-09-30 | $21.56M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $45.03M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $45.03M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $193.83M 10-K · filed 2025-03-27 |
| 2024-09-30 | $159.90M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $159.90M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $159.90M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $20.59M 10-K · filed 2024-03-19 |
| 2023-09-30 | $20.55M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $18.75M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $18.70M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $10.63M 10-K · filed 2023-03-23 |
| 2022-09-30 | $6.47M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $6.47M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $6.47M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $6.47M 10-K · filed 2022-03-10 |
| 2021-09-30 | $6.56M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $6.56M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $9.51M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $4.70M 10-K · filed 2021-03-08 |
| 2020-09-30 | $4.44M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $5.43M 10-Q · filed 2020-08-10 |
| 2018-03-31 | $3.44M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $3.66M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |